1 / 11

Chemotherapy Induced Peripheral Neuropathy Market

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib.<br>

DelveInsight
Download Presentation

Chemotherapy Induced Peripheral Neuropathy Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHEMOTHAREPY INDUCED PERIPHERAL NEUROPATHY Market Insights, Epidemiology and Market Forecast - 2027 Delveinsight © 2018 | All rights reserved

  2. INTRODUCTION With the exception of paclitaxel and oxaliplatin, which causes an acute neuropathy that emerges either during or shortly after infusion, the onset of CIPN is usually delayed and appears to depend on the total cumulative dose. Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors. Delveinsight © 2018 | All rights reserved

  3. Prevalence of CIPN FROM 2016 - 2027 Delveinsight © 2018 | All rights reserved

  4. MARKETSIZE The market size of currently prescribed offlabel therapies for the treatment of CIPN is expected to initially experience steady growth, and will further decrease owing to the launch of upcoming therapies in forecast period [2018-2027] Expected launch of SP-04 (Solasia), Tetrodotoxin (WEX Pharmaceuticals), and E-52862 (Esteve) during the forecast period (2018-2027) may create a positive impact on the CIPN market 02 04 01 03 05 The assessment of CIPN is not standardized and thus acts as a restraint in the therapeutic market of this indication. Owing to the launch of promising therapies, market size is expected to increase in the G8, during the forecast period (2018-2027) Companies are focused on the development of targeted therapies for the treatment of CIPN, which are expected to create an evident impact on the market revenue in coming years Delveinsight © 2018 | All rights reserved

  5. EMERGING DRUGS AND COMPANIES Chroma Dex NIAGEN DARA Biosciences Medicinova MN - 166 KRN 5500 3 2 4 Apollo Endosurgery WEX Pharmaceuticals DRUGS 5 1 Tetrodotoxin Lpathomab Delveinsight © 2018 | All rights reserved

  6. About delveinsight about mISSION vision 01 02 03 • DelveInsight, market research and consulting firm, provides end to end comprehensive solutions to the Life Science Industry • We help our customers in best decision making through our expertise in research & analysis and comes out with unmatched data & forecasts • “insight across the value chain” to help organizations make important business decisions through the use and analysis of actionable market intelligence • To be the most trusted marketing research firm & business consulting firm world wide. To be a renowned and premier data driven solution providers among Pharma & Biotech companies Delveinsight © 2018 | All rights reserved

  7. Services Offered By Delveinsight 6 8 7 5 1 2 3 4 Competitive Analysis Consulting Report Store Pipeline Opportunity Assessment Forecasting Socialytics Market Intelligence Delveinsight © 2018 | All rights reserved

  8. REPORT PRICE CORPORATE LICENSE $18750 2-3 USER LICENSE SITE LICENSE $9500 SINGLE USER $12500 $6250 Delveinsight © 2018 | All rights reserved

  9. CONTACT US info@delveinsight.com +91-11-4568 9769 www.delveinsight.com blog/delveInsight twitter/delveInsight LinkedIn/delveInsight Delveinsight © 2018 | All rights reserved

  10. complete INFORMATION For Complete Information please Click below Click here Or Write us at info@delveinsight.com Delveinsight © 2018 | All rights reserved

  11. Delveinsight © 2018 | All rights reserved

More Related